MNG683
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.415
- NOTCH_SIGNALING+0.370
- ANDROGEN_RESPONSE+0.367
- CHOLESTEROL_HOMEOSTASIS+0.351
- TGF_BETA_SIGNALING+0.338
- PROTEIN_SECRETION+0.311
- TNFA_SIGNALING_VIA_NFKB+0.307
- WNT_BETA_CATENIN_SIGNALING+0.285
- G2M_CHECKPOINT+0.243
- UV_RESPONSE_DN+0.233
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.246
- OXIDATIVE_PHOSPHORYLATION-0.241
- INTERFERON_GAMMA_RESPONSE-0.238
- INTERFERON_ALPHA_RESPONSE-0.225
- IL6_JAK_STAT3_SIGNALING-0.181
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.138
- P53_PATHWAY-0.113
- MTORC1_SIGNALING-0.099
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.099
- KRAS_SIGNALING_UP-0.084
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1193 | — | — | 0.883 |
| 2 | MNG1026 | — | — | 0.783 |
| 3 | MNG1104 | — | — | 0.774 |
| 4 | C138638F-C6CB-439B-BFF0-CF097E0B421E | — | — | 0.764 |
| 5 | SRR934758 | — | — | 0.753 |
| 6 | SRR934850 | — | — | 0.749 |
| 7 | 37415C2E-3112-47E6-8757-4D128E3447AE | — | — | 0.743 |
| 8 | MNG1077 | — | — | 0.739 |
| 9 | SRR934820 | — | — | 0.713 |
| 10 | 2B70C69F-DE54-4C78-B326-5CCEE15916FB | — | — | 0.712 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.415 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.367 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.351 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.338 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.311 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.307 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.285 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.243 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.233 | Inavolisib | — uncovered |
| APOPTOSIS | 0.219 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.218 | Inavolisib | — uncovered |
| PEROXISOME | 0.208 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.177 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.167 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.121 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.117 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.113 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.102 | Idelalisib | — uncovered |